HK1068546A1 - Combination therapy comprising zd6474 and taxane - Google Patents

Combination therapy comprising zd6474 and taxane

Info

Publication number
HK1068546A1
HK1068546A1 HK05100883A HK05100883A HK1068546A1 HK 1068546 A1 HK1068546 A1 HK 1068546A1 HK 05100883 A HK05100883 A HK 05100883A HK 05100883 A HK05100883 A HK 05100883A HK 1068546 A1 HK1068546 A1 HK 1068546A1
Authority
HK
Hong Kong
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
HK05100883A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1068546A1 publication Critical patent/HK1068546A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05100883A 2001-11-08 2005-02-03 Combination therapy comprising zd6474 and taxane HK1068546A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
HK1068546A1 true HK1068546A1 (en) 2005-04-29

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100883A HK1068546A1 (en) 2001-11-08 2005-02-03 Combination therapy comprising zd6474 and taxane

Country Status (23)

Country Link
US (2) US20050043395A1 (da)
EP (1) EP1446124B1 (da)
JP (1) JP4694127B2 (da)
KR (1) KR100959607B1 (da)
CN (1) CN1298328C (da)
AR (1) AR037346A1 (da)
AT (1) ATE335488T1 (da)
AU (1) AU2002337382B2 (da)
BR (1) BR0213906A (da)
CA (1) CA2464758C (da)
CY (1) CY1106259T1 (da)
DE (1) DE60213845T2 (da)
DK (1) DK1446124T3 (da)
ES (1) ES2269769T3 (da)
GB (1) GB0126879D0 (da)
HK (1) HK1068546A1 (da)
IL (2) IL161744A0 (da)
MX (1) MXPA04004355A (da)
NO (1) NO328048B1 (da)
NZ (1) NZ532525A (da)
PT (1) PT1446124E (da)
WO (1) WO2003039551A1 (da)
ZA (1) ZA200403455B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626A0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
PT1474420E (pt) 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PL215161B1 (pl) 2002-11-04 2013-10-31 Astrazeneca Ab Pochodne chinazoliny, sposób ich wytwarzania, kompozycje farmaceutyczne je zawierajace oraz ich zastosowanie
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
NZ544458A (en) * 2003-07-10 2009-04-30 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
CN101553253A (zh) * 2006-09-29 2009-10-07 阿斯利康(瑞典)有限公司 用于癌症治疗的zd6474和贝伐单抗的组合
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
NZ589883A (en) * 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
DE60011612T2 (de) * 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
NZ518028A (en) * 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
NZ544458A (en) * 2003-07-10 2009-04-30 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
CN101553253A (zh) * 2006-09-29 2009-10-07 阿斯利康(瑞典)有限公司 用于癌症治疗的zd6474和贝伐单抗的组合

Also Published As

Publication number Publication date
NZ532525A (en) 2006-11-30
PT1446124E (pt) 2006-12-29
CN1612738A (zh) 2005-05-04
IL161744A0 (en) 2005-11-20
MXPA04004355A (es) 2004-08-11
KR20050043779A (ko) 2005-05-11
WO2003039551A1 (en) 2003-05-15
GB0126879D0 (en) 2002-01-02
US20120252827A1 (en) 2012-10-04
IL161744A (en) 2012-01-31
CY1106259T1 (el) 2011-06-08
NO328048B1 (no) 2009-11-16
CA2464758C (en) 2010-09-28
ES2269769T3 (es) 2007-04-01
KR100959607B1 (ko) 2010-05-27
JP2005511597A (ja) 2005-04-28
US20050043395A1 (en) 2005-02-24
CA2464758A1 (en) 2003-05-15
EP1446124A1 (en) 2004-08-18
AU2002337382B2 (en) 2008-06-12
ATE335488T1 (de) 2006-09-15
NO20042365L (no) 2004-06-07
DE60213845T2 (de) 2007-03-29
AR037346A1 (es) 2004-11-03
EP1446124B1 (en) 2006-08-09
ZA200403455B (en) 2005-08-29
JP4694127B2 (ja) 2011-06-08
CN1298328C (zh) 2007-02-07
BR0213906A (pt) 2004-08-31
DE60213845D1 (de) 2006-09-21
DK1446124T3 (da) 2006-11-13

Similar Documents

Publication Publication Date Title
HK1068546A1 (en) Combination therapy comprising zd6474 and taxane
GB0111872D0 (en) Therapeutic agents and methods
EP1463438A4 (en) ENDOMURAL THERAPY
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002346504A8 (en) Therapeutic protein and treatments
PL369510A1 (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
GB0114014D0 (en) Compostion and use
GB0212405D0 (en) Composition and its therapeutic use
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0119025D0 (en) Compounds and their therapeutic use
GB0108485D0 (en) Combination therapy
EP1701736A4 (en) THERAPEUTIC AGENTS AND ITS USES
IL147696A0 (en) Combination therapy
EP1367123A4 (en) NEUROTONIN AND ITS USE
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0201615D0 (en) Compounds and their therapeutic use
GB0124029D0 (en) Combination therapy
GB0130733D0 (en) Therapeutic compounds and their use in therapy
GB0116969D0 (en) Neuro-phototransduction device and treatment
GB0108821D0 (en) Therapy
GB0108817D0 (en) Therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131106